NHS to offer new drug that halves the risk of cancer returning
A world-leading treatment that halves the risk of lung cancer patients suffering a return of the disease after undergoing treatment, is to be rolled out by NHS England.
In a trial of the drug – the first of its kind – around nine out of ten patients treated, remained alive and disease-free after two years – compared to more than four in ten who hadn’t received the new therapy.
Lung cancer is the most common cause of cancer death in the UK, accounting for one in five of all cancer deaths.
Around 100 patients in England with a rare form of cancer will initially have access to the drug, called Osimertinib, with many more expected to benefit this year.
Eligible patients with rare forms of early-stage non-small cell lung cancer will be offered the drug, which catches the tumour early, stopping it developing and potentially increasing the chance of surviving the disease.
Osimertinib is the first treatment for patients with non-small cell lung cancer whose tumours have a specific type of genetic mutation, to be licensed for use in patients who have just had surgery.
Sir Simon Stevens, NHS chief executive, said:
“The NHS has continued to offer new treatments rapidly throughout the pandemic, to improve care for patients, including a package of COVID-safe treatments for cancer.
“This new drug, which halves the chance of lung cancer returning, is the latest potentially life-saving drug deal landed by the NHS in England, following agreements that have led to sight loss treatment for children and cystic fibrosis therapy brought to frontline patient care.
“The NHS message to anyone experiencing symptoms such as a cough for three weeks or more is clear – do not delay, help us to help you by coming forward for care – the NHS is ready and able to treat you, often with the most cutting-edge treatments available anywhere in the world.”
NHS England, NICE and AstraZeneca have reached an agreement to enable early access to Osimertinib for early-stage lung cancer patients in England on a budget-neutral basis to the NHS while NICE undertakes its appraisal.
The deal follows the first drug licence issued by the MHRA as part of the Orbis programme – an international partnership between medicines regulators in the UK, U.S., Australia and others, set up to speed up the approval process for promising cancer treatments, and hoped to benefit other patients in England this year.
Osimertinib was discovered and developed in the UK and is already used to treat NHS patients with other forms of advanced lung cancer.
The NHS Long Term Plan committed to increasing the number of tumours caught at an early stage from half to three in four.
The announcement is the latest in a series of innovations in cancer care during the pandemic, including COVID-secure surgery hubs that were set up across the country and £160 million invested by NHS England in ‘COVID-friendly’ cancer drugs, that treat patients without having such a big impact on their immune system or offer other benefits such as fewer hospital visits.
Cancer treatment continued during the pandemic with almost 300,000 people starting treatment for cancer and more than 2.2 million were referred for checks.
The NHS is currently running a campaign to encourage people who have had a cough for three weeks or longer to get checked.
Latest News from
Eliminating the risk of inadvertent connection to medical air via a flowmeter16/06/2021 12:30:00
A National Patient Safety Alert has been issued asking all providers that use piped medical air to eliminate the risk of inadvertently connecting patients to medical air via a flowmeter instead of oxygen.
21 and 22 year olds to be offered COVID-19 jab from today16/06/2021 11:10:00
Around one million people aged 21 and 22 will begin to be called forward this morning to get the coronavirus vaccine, as the NHS COVID Vaccination Programme enters the final phase of the first dose roll-out.
Patients with type 1 diabetes to get artificial pancreas on the NHS15/06/2021 16:20:00
An ‘artificial pancreas’ designed to revolutionise the life of people with Type 1 diabetes will be provided by the NHS, 100 years after the discovery of insulin, health service chief executive Sir Simon Stevens announced today.
NHS sets up specialist young people’s services in £100 million long COVID care expansion15/06/2021 14:20:00
The NHS is setting up specialist long COVID services for children and young people as part of a £100 million expansion of care for those suffering from the condition.
NHS pelvic health clinics to help tens of thousands women across the country15/06/2021 09:15:00
Tens of thousands of pregnant women and new mums will receive support to prevent and treat incontinence and other pelvic floor issues, thanks to new clinics set up by the NHS.
Three in four people with a learning disability receive NHS annual health check14/06/2021 09:15:00
Three quarters of people with a learning disability aged 14 and over have received an annual health check two years ahead of an NHS Long Term Plan target.
NHS ahead of target in recovery of elective care, and mental health services back to pre-pandemic levels11/06/2021 09:15:00
Operations and other routine care are ahead of ambitions set out in April with mental health services back at pre-pandemic levels, NHS figures show.
Young people deliver record-breaking day for NHS COVID-19 jab bookings10/06/2021 10:25:00
There were more than one million bookings for a COVID-19 vaccine through the NHS website on Tuesday 8 June, a record high figure and the first time daily appointments booked through the national booking service have topped the million mark.
Anne Longfield appointed by NHS to help transform care of children and young people with a learning disability and autism09/06/2021 16:05:00
The NHS has appointed former Children’s Commissioner Anne Longfield OBE to help transform the care of children and young people with a learning disability and autism.